Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 1997Website:
http://vcel.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 20:47:43 GMTDividend
Analysts recommendations
Institutional Ownership
VCEL Latest News
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration Targets the Largest Segment of MACI's $3 Billion Addressable Market CAMBRIDGE, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) expanding the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label to include arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size.
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) for eschar removal in pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Vericel (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Vericel Corporation (VCEL) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
Total Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million NexoBrid Revenue Growth of 76% Over Prior Quarter Gross Margin of 70% and Adjusted EBITDA Growth of 42% Full-Year Profitability Guidance Raised to 71% Gross Margin and 21% Adjusted EBITDA Margin Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2024.
CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010.
CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.
Vericel Corporation (VCEL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
What type of business is Vericel?
Vericel Corporation is a leader in advanced cell therapy methods and specialized biopreparations for the sports medicine and severe burn treatment markets. The company was founded in 1989. The headquarters, research division, all commercial and manufacturing operations are carried out at one facility located in Cambridge, Massachusetts. The company's products, based on the principles of autologous cell therapy, include Epicel, which is a bio-material permanent skin substitute for treating patients with deep skin burns or full-thickness skin burns. The company is also developing MACI - a third-generation autologous chondrocyte implant and the personalized multicellular therapy drug ixmyelocel-T.
What sector is Vericel in?
Vericel is in the Healthcare sector
What industry is Vericel in?
Vericel is in the Biotechnology industry
What country is Vericel from?
Vericel is headquartered in United States
When did Vericel go public?
Vericel initial public offering (IPO) was on 04 February 1997
What is Vericel website?
https://vcel.com
Is Vericel in the S&P 500?
No, Vericel is not included in the S&P 500 index
Is Vericel in the NASDAQ 100?
No, Vericel is not included in the NASDAQ 100 index
Is Vericel in the Dow Jones?
No, Vericel is not included in the Dow Jones index
When was Vericel the previous earnings report?
No data
When does Vericel earnings report?
The next expected earnings date for Vericel is 08 November 2024